Cargando…
Treatment Recommendations for Adult Patients with Diffuse Gliomas of Grades II and III According to the New WHO Classification in 2016
With advanced understanding of molecular background and correlation with therapeutic outcomes, the revised 4th edition of World Health Organization (WHO) classification of central nervous system (CNS) tumors incorporated molecular information into the definition of diffuse gliomas. Indeed, oligodend...
Autores principales: | SASAKI, Hikaru, YOSHIDA, Kazunari |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Japan Neurosurgical Society
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5735229/ https://www.ncbi.nlm.nih.gov/pubmed/28845038 http://dx.doi.org/10.2176/nmc.ra.2017-0071 |
Ejemplares similares
-
MNG-03 PD-L1 EXPRESSION, PATIENT PROGNOSIS AND INITIAL WHO GRADE IN GRADE II/III MENINGIOMA
por: Kamamoto, Dai, et al.
Publicado: (2019) -
Bevacizumab in recurrent WHO grades II–III glioma
por: Annakib, Soufyan, et al.
Publicado: (2023) -
S4-KL-1 UPDATE OF WHO2016 CLASSIFICATION OF ADULT DIFFUSE GLIOMAS
por: Komori, Takashi
Publicado: (2019) -
DNA methylation signatures for 2016 WHO classification subtypes of diffuse gliomas
por: Paul, Yashna, et al.
Publicado: (2017) -
Current therapeutic approaches to diffuse grade II and III gliomas
por: Picca, Alberto, et al.
Publicado: (2018)